Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05973149 | Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer | unknown | Phase 1 | 108 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05005299 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) |
| unknown |
| Phase 1 |
| 18 |
| Melbourne HealthOTHER |
| 1 |
| Aug 1, 2023 |
| clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05845138 | A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. | unknown | Phase 1 / Phase 2 | 116 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05911789 | Online Adaptive Radiation Therapy for Rectal Cancer | unknown | Phase 1 / Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05970822 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | unknown | Phase 1 | 32 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05783921 | A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05965102 | Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer | unknown | Phase 1 | 31 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05965141 | Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer | unknown | Phase 1 / Phase 2 | 38 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Jul 28, 2023 | clinicaltrials |
| NCT05226468 | An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | unknown | Phase 1 | 24 | New Epsilon Innovation LimitedINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05333276 | Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers | unknown | Phase 1 | 7 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05074550 | Safety Evaluation Study for Patients With Polycythemia Vera | unknown | Phase 1 | 6 | Perseus Proteomics Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05957640 | Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 40 | Zhongda HospitalOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05886374 | A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 81 | HutchmedINDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05396391 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | unknown | Phase 1 / Phase 2 | 140 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05396339 | A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 120 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05949762 | Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05089266 | Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors | unknown | Phase 1 | 30 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05731518 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | unknown | Phase 1 / Phase 2 | 67 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT04836871 | Double Filtration Plasmapheresis Combined With Chemotherapy | unknown | Phase 1 | 20 | Fuling ZhouOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04522050 | Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 | 65 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05867563 | Clinical Trial Evaluating the Safety of the TQB2103 for Injection | unknown | Phase 1 | 71 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT05928962 | An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas | unknown | Phase 1 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05451407 | Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05851092 | Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors | unknown | Phase 1 | 60 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03803397 | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03989895 | Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT03990493 | Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma | unknown | Phase 1 | 10 | PrimeVax Immuno-Oncology Inc.INDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT04967690 | A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM(TARGLIO) | unknown | Phase 1 | 27 | Double Bond Pharmaceutical ABINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05631912 | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL | unknown | Phase 1 / Phase 2 | 38 | Chinese PLA General HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05927779 | Study of TFX06 in Women With Advanced Breast Cancer. | unknown | Phase 1 / Phase 2 | 74 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05927844 | XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma | unknown | Phase 1 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Jul 3, 2023 | clinicaltrials |
| NCT05929456 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)(MIRROR) | unknown | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05920876 | A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma | unknown | Phase 1 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02786589 | Plasmodium Immunotherapy for Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | State Key Laboratory of Respiratory DiseaseOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04803851 | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 29 | Peking Union Medical College HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04850235 | Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study | unknown | Phase 1 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05911984 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 27 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03090659 | LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma(LEGEND-2) | unknown | Phase 1 / Phase 2 | 100 | Nanjing Legend Biotech Co.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05898373 | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC | unknown | Phase 1 / Phase 2 | 120 | Peking Union Medical CollegeOTHER | 0 | Jun 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 2, 2023source: clinicaltrials